+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Corticosteroids and Anti-Complement Therapy in Retinal Diseases



Corticosteroids and Anti-Complement Therapy in Retinal Diseases



Handbook of Experimental Pharmacology 242: 309-320



Corticosteroids are unique in that they are the one class of agents that acts upon most of the multiple processes in the pathophysiology of macular edema. Corticosteroids are capable of inhibiting prostaglandin and leukotriene synthesis as well as interfering with intercellular adhesion molecule-1 (ICAM-1), interleukin-6, VEGF-A, and stromal cell derived factor-1 pathways. Triamcinolone, dexamethasone, and fluocinolone have been extensively used in the treatment of retinal and choroidal vascular diseases. Sustained release implants of steroids have reduced the burden of repeated intravitreal injections necessary in most of the retinal diseases. Complement factors play an important role in the pathogenesis of age-related macular degeneration (AMD). Inhibitors of complement could provide a breakthrough in the treatment of dry AMD. Complement factor inhibitors, such as POT-4, lampalizumab, and eculizumab, have been tested in clinical trials for dry AMD with promising results. However, results of phase 3 trials are awaited.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057525911

Download citation: RISBibTeXText

PMID: 27815789

DOI: 10.1007/164_2016_22


Related references

Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. American Journal of Ophthalmology 180: 8-17, 2017

Anti-complement therapy for glomerular diseases. Advances in Chronic Kidney Disease 21(2): 152-158, 2014

Anti-tuberculous therapy combined with systemic corticosteroids improves retinal sensitivity in patients with active presumed tuberculous choroiditis. International Ophthalmology 30(5): 567-576, 2011

Anti complement c 3d anti globulin reagents part 1 characteristics of the anti complement c 3 and anti complement c 3d responses during hyper immunization in rabbits. Transfusion (bethesda): 407-415, 1974

A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases. Journal of Telemedicine and Telecare 19(8): 437-442, 2014

Internal medicine diseases and anti-thrombotic therapy. Anti-thrombotic therapy for arteriosclerotic diseases. Ischemic heart diseases ( thrombolytic therapy ). Nihon Naika Gakkai Zasshi 86(9): 1625-1628, 1997

Internal medicine diseases and anti-thrombotic therapy. Anti-thrombotic therapy for arteriosclerotic diseases. Ischemic heart diseases ( antiplatelet therapy ). Nihon Naika Gakkai Zasshi 86(9): 1621-1624, 1997

An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents. Current Drug Therapy 6(1): 35-50, 2011

The complement uptake reaction as a test for detecting anti-hepatic complement-fixing antibodies in diseases of the liver. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 42(8): 84-87, 1965

Corticosteroids in the treatment of gynecologic inflammatory diseases. In: 1st International Symposium on Anti-infectious and Anti-mitotic Chemotherapy. Antibiot Et Chemother 8: 356-358, 1960

Complement dependent immune phagocytosis i requirements for complement 1 complement 4 complement 2 complement 3 sheep erythrocyte guinea pig rabbit anti serum. Experimental Cell Research 51(7): 45-67, 1968

Method for treating and/or preventing retinal diseases with sustained release corticosteroids. Official Gazette of the United States Patent & Trademark Office Patents 1245(3), Apr 17, 2001

The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?. Pediatric Nephrology 2018, 2018

Effects of six topical corticosteroids on DNA synthesis of normal human skin fibroblasts--in vitro evaluation of anti-proliferative possibly anti-inflammatory potencies of corticosteroids. Tokushima Journal of Experimental Medicine 35(1-2): 1-4, 1988

Internal medicine diseases and anti-thrombotic therapy. Anti-thrombotic therapy for arteriosclerotic diseases. Symptomatic/asymptomatic cerebral infarction. Nihon Naika Gakkai Zasshi 86(9): 1617-1620, 1997